Physician Assistant Program year 2025 Reported 2023–2025 Source: CMS Open Payments, 2026 publication

Siena Saluzzo

Physician Assistant Catonsville, MD Physician Assistant

NPI 1982389185 CMS profile 11546817

700 Geipe Rd Ste 200, Catonsville, MD 21228

Open in the dashboard

General payments

$3,621

125 records reported · program years 2023–2025

Research payments

$0

Paid to them · None reported · program years 2023–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Siena Saluzzo of Catonsville, MD is reported in the CMS Open Payments database as having received $3,621 across 125 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,064 72
2024 General $1,252 43
2023 General $305 10

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Siena Saluzzo
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Siena Saluzzo were reported at $2,064. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Siena Saluzzo Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $0 $132 $37–$438 $132
2022 $0 $155 $48–$522 $149
2023 $305 $167 $52–$557 $160
2024 $1,252 $178 $55–$600 $164
2025 $2,064 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2023–2025
  1. Janssen Biotech, Inc. $644 16 payments
  2. Amgen Inc. $502 22 payments
  3. AbbVie, Inc. $462 14 payments
  4. AstraZeneca Pharmaceuticals LP $321 5 payments
  5. Mallinckrodt Hospital Products Inc. $208 6 payments
  6. UCB, Inc. $203 10 payments
  7. Pfizer Inc. $200 10 payments
  8. Fresenius Kabi USA, LLC $160 7 payments
  9. Horizon Therapeutics plc $154 2 payments
  10. Organon LLC $147 7 payments
  11. Other $619 26 payments

Every payment, record by record

What the payments were for General payments · program years 2023–2025
  1. Food and Beverage $3,451 123 payments
  2. Education $170 2 payments
Products named General payments · program years 2023–2025
  1. TREMFYA $690 18 payments
  2. KRYSTEXXA Inflammation/Rare Disease $364 15 payments
  3. SAPHNELO $321 5 payments
  4. SKYRIZI $273 6 payments
  5. ACTHAR $208 6 payments
  6. SIMPONI ARIA $200 2 payments
  7. RINVOQ $189 8 payments
  8. XELJANZ $183 9 payments
  9. KRYSTEXXA Krystexxa $154 2 payments
  10. HADLIMA $147 7 payments
  11. Other $1,298 59 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

277

Median for Physician Assistant: 241

Drug cost

$12,009

Median for Physician Assistant: $4,110

Branded share of claims

13%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydroxychloroquine Sulfate Generic 93 $7,708
Methotrexate Methotrexate Sodium Brand 36 $1,726
Leflunomide Generic 34 $1,640
Tramadol Hcl Generic 56 $389
Allopurinol Generic 20 $236
Prednisone Generic 24 $170
Folic Acid Generic 14 $141

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
KRYSTEXXA
  • Amgen Inc. $172
$172 — —
ACTHAR
  • Mallinckrodt Hospital Products Inc. $164
$164 — —
TREMFYA
  • Janssen Biotech, Inc. $123
$123 — —
SAPHNELO
  • AstraZeneca Pharmaceuticals LP $118
$118 — —
XELJANZ
  • PFIZER INC. $114
$114 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

125 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record